RC48, an ADC composed of a humanized anti-HER2 monoclonal antibody (hertuzumab) conjugated via a cleavable linker to the microtubule inhibitor monomethyl auristatin E (MMAE), which have been approved for the treatment of advanced or metastatic HER2-positive gastric cancer and urothelial cancer [20–22]. Here, ERBB2 is linked to gastric cancer.